Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Central stimulant, selective inhibitor of dopamine and norepinephrine reuptake. Modafinil is a racemic mixture of its R enantiomer and its S enantiomer. The R enantiomer, known as armodafinil, is pharmacologically active, while the S enantiomer is inactive (Aurora 2018). Used in narcolepsy. Oral administration in one or two daily doses.
Modafinil is excreted in breastmilk in clinically insignificant amounts (Aurora 2018) and no problems have been observed in six infants whose mothers were taking modafinil. (Calvo 2018)
Modafinil can reduce prolactin levels. (Samuels 2006)
A mother reported to us in 2020 nervousness and sleeping difficulties in her breastfed daughters, which forced her to suspend treatment (age of girls and doses unspecified).
Until there is further published data on this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in cases of prematurity.
See below the information of these related products: